1
|
Hallowell BD, Chavers T, Parashar U, Tate JE. Global Estimates of Rotavirus Hospitalizations Among Children Below 5 Years in 2019 and Current and Projected Impacts of Rotavirus Vaccination. J Pediatric Infect Dis Soc 2022; 11:149-158. [PMID: 34904636 DOI: 10.1093/jpids/piab114] [Citation(s) in RCA: 7] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/01/2021] [Accepted: 11/15/2021] [Indexed: 12/22/2022]
Abstract
BACKGROUND Rotavirus vaccine impact on rotavirus hospitalizations is not well documented globally. We performed a systematic review to estimate the number of rotavirus hospitalizations that (1) occur annually, (2) are currently prevented by rotavirus vaccines, and (3) could be prevented with improved vaccine coverage and universal vaccine introduction. METHODS We systematically reviewed articles indexed in the PubMed database published from January 1, 2000, to December 31, 2019. We included all primary peer-reviewed studies with rotavirus hospitalization rates for children below 5 years that reported data prior to vaccine introduction, utilized at least one continuous year of data collection, and collected hospitalization data after 2000 using active surveillance. We grouped pre-vaccine country estimates by childhood mortality strata and calculated the median rate among each group. We then assigned the mortality stratum-specific hospitalization rates to each country and calculated the number of rotavirus hospitalizations by country, mortality strata, and World Health Organization region. RESULTS Our search strategy identified 4590 manuscripts, of which 32 were included in the final dataset. In 2019, an estimated 1 760 113 (interquartile range [IQR]: 1 422 645-2 925 372) rotavirus hospitalizations occurred globally, with 524 871 (IQR: 415 987-814 835) prevented by rotavirus vaccination. With universal introduction of rotavirus vaccines and increased vaccine coverage, we estimate that an additional 751 609 (IQR: 607 671-1 318 807) rotavirus hospitalizations can be prevented annually. CONCLUSIONS This analysis highlights the continued burden of rotavirus hospitalizations among children below 5 years. A large, preventable proportion of this burden could be eliminated by expanding introductions to new countries and increasing rotavirus vaccine coverage to levels seen with other childhood vaccinations.
Collapse
Affiliation(s)
- Benjamin D Hallowell
- Division of Viral Diseases, Centers for Disease Control and Prevention, Atlanta, GeorgiaUSA.,Epidemic Intelligence Service, Centers for Disease Control and Prevention, Atlanta, GeorgiaUSA
| | - Tyler Chavers
- Division of Viral Diseases, Centers for Disease Control and Prevention, Atlanta, GeorgiaUSA
| | - Umesh Parashar
- Division of Viral Diseases, Centers for Disease Control and Prevention, Atlanta, GeorgiaUSA
| | - Jacqueline E Tate
- Division of Viral Diseases, Centers for Disease Control and Prevention, Atlanta, GeorgiaUSA
| |
Collapse
|
2
|
Ardura-Garcia C, Kreis C, Rakic M, Jaboyedoff M, Mallet MC, Low N, Kuehni CE. Rotavirus disease and health care utilisation among children under 5 years of age in highly developed countries: A systematic review and meta-analysis. Vaccine 2021; 39:2917-2928. [PMID: 33934916 DOI: 10.1016/j.vaccine.2021.04.039] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/15/2020] [Revised: 04/16/2021] [Accepted: 04/17/2021] [Indexed: 10/21/2022]
Abstract
BACKGROUND Rotavirus (RV) infection is the leading cause of diarrhoea-associated morbidity and mortality globally among children under 5 years of age. RV vaccination is available, but has not been implemented in many national immunisation plans, especially in highly developed countries. This systematic review aimed to estimate the prevalence and incidence of health care use for RV gastroenteritis (RVGE) among children aged under 5 years in highly developed countries without routine RV vaccination. METHODS We searched MEDLINE and Embase databases from January 1st 2000 to December 17th 2018 for publications reporting on incidence or prevalence of RVGE-related health care use in children below 5 years of age: primary care and emergency department (ED) visits, hospitalisations, nosocomial infections and deaths. We included only studies with laboratory-confirmed RV infection, undertaken in highly developed countries with no RV routine vaccination plans. We used random effects meta-analysis to generate summary estimates with 95% confidence intervals (CI) and prediction intervals. RESULTS We screened 4033 abstracts and included 74 studies from 21 countries. Average incidence rates of RVGE per 100 000 person-years were: 2484 (95% CI 697-5366) primary care visits, 1890 (1597-2207) ED visits, 500 (422-584) hospitalisations, 34 (20-51) nosocomial infections and 0.04 (0.02-0.07) deaths. Average proportions of cases of acute gastroenteritis caused by RV were: 21% (95% CI 16-26%) for primary care visits; 32% (25-38%) for ED visits; 41% (36-47%) for hospitalisations, 29% (25-34%) for nosocomial infections and 12% (8-18%) for deaths. Results varied widely between and within countries, and heterogeneity was high (I2 > 90%) in most models. CONCLUSION RV in children under 5 years causes many healthcare visits and hospitalisations, with low mortality, in highly developed countries without routine RV vaccination. The health care use estimates for RVGE obtained by this study can be used to model RV vaccine cost-effectiveness in highly developed countries.
Collapse
Affiliation(s)
- Cristina Ardura-Garcia
- Institute of Social and Preventive Medicine, University of Bern, Mittlestrasse 43, 3012 Bern, Switzerland
| | - Christian Kreis
- Institute of Social and Preventive Medicine, University of Bern, Mittlestrasse 43, 3012 Bern, Switzerland
| | - Milenko Rakic
- Institute of Social and Preventive Medicine, University of Bern, Mittlestrasse 43, 3012 Bern, Switzerland
| | - Manon Jaboyedoff
- Service of Paediatrics, Department Women-Mother-Child, Lausanne University Hospital and University of Lausanne, Rue de Bugnon 21, 1011 Lausanne, Switzerland
| | - Maria Christina Mallet
- Institute of Social and Preventive Medicine, University of Bern, Mittlestrasse 43, 3012 Bern, Switzerland; Graduate School for Health Sciences, University of Bern, Mittlestrasse 43, 3012 Bern, Switzerland
| | - Nicola Low
- Institute of Social and Preventive Medicine, University of Bern, Mittlestrasse 43, 3012 Bern, Switzerland
| | - Claudia E Kuehni
- Institute of Social and Preventive Medicine, University of Bern, Mittlestrasse 43, 3012 Bern, Switzerland; Paediatric Respiratory Medicine, Children's University Hospital of Bern, University of Bern, Freiburgstrasse, 3010 Bern, Switzerland.
| |
Collapse
|
3
|
Prelog M, Gorth P, Zwazl I, Kleines M, Streng A, Zlamy M, Heinz-Erian P, Wiedermann U. Universal Mass Vaccination Against Rotavirus: Indirect Effects on Rotavirus Infections in Neonates and Unvaccinated Young Infants Not Eligible for Vaccination. J Infect Dis 2016; 214:546-55. [PMID: 27190178 DOI: 10.1093/infdis/jiw186] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/18/2016] [Accepted: 04/27/2016] [Indexed: 12/15/2022] Open
Abstract
BACKGROUND Rotavirus (RV)-associated infections account for high numbers of hospitalizations in neonates and young infants. Universal mass vaccination (UMV) has been shown to prevent the burden of disease in vaccinated children. METHODS The present study investigated the long-term effects of UMV on RV-associated hospitalizations in children with particular focus on neonates and young infants (≤42 days old) not eligible for vaccination. Ten years of Austrian surveillance data were compared, including 10 960 laboratory-confirmed RV cases before (prevaccination period [PreVP]) and after (postvaccination period [PostVP]) introduction of UMV. RESULTS A postvaccination decrease in hospitalized community-acquired RV infections by 89.3% was seen in all age groups, including unvaccinated neonates and young infants. Of the latter, 27.6% had a nosocomial RV infection in PreVP, and 19.3% in PostVP. Overall, the proportion of nosocomial RV infections increased from 5.5% in PreVP to 13.0% in PostVP. Breakthrough infections, usually after incomplete RV vaccination, could be identified in 6.2% of patients. CONCLUSIONS Unvaccinated neonates and infants ≤42 days old may indirectly benefit from UMV by reduction of RV infections. Breakthrough infections underline the importance of early and complete protection by the vaccine. In older patients, heightened awareness of nosocomial RV infections is warranted. Identification of RV reservoirs is also needed.
Collapse
Affiliation(s)
| | - Peter Gorth
- Department of Pediatrics, University Hospital Wuerzburg
| | - Ines Zwazl
- Institute of Specific Prophylaxis and Tropical Medicine, Medical University Vienna
| | - Michael Kleines
- Department of Medical Microbiology, University Hospital Aachen, Rheinisch-Westfälische Technische Hochschule Aachen University, Germany Division of Virology, Medical University Innsbruck, Austria
| | - Andrea Streng
- Department of Pediatrics, University Hospital Wuerzburg
| | | | | | - Ursula Wiedermann
- Institute of Specific Prophylaxis and Tropical Medicine, Medical University Vienna
| |
Collapse
|
4
|
Abstract
Rotavirus gastroenteritis is a vaccine-preventable disease that confers a high medical and economic burden in more developed countries and can be fatal in less developed countries. Two vaccines with high efficacy and good safety profiles were approved and made available in Europe in 2006. We present an overview of the status of rotavirus vaccination in Europe. We discuss the drivers (including high effectiveness and effect of universal rotavirus vaccination) and barriers (including low awareness of disease burden, perception of unfavourable cost-effectiveness, and potential safety concerns) to the implementation of universal rotavirus vaccination in Europe. By February, 2014, national universal rotavirus vaccination had been implemented in Belgium, Luxembourg, Austria, Finland, Greece, Luxembourg, Norway, and the UK. Four other German states have issued recommendations and reimbursement is provided by sickness funds. Other countries were at various stages of recommending or implementing universal rotavirus vaccination.
Collapse
|
5
|
Zhou X, Zhou Y, Chen R, Ma W, Deng H, Kan H. High temperature as a risk factor for infectious diarrhea in Shanghai, China. J Epidemiol 2013; 23:418-23. [PMID: 23994865 PMCID: PMC3834278 DOI: 10.2188/jea.je20130012] [Citation(s) in RCA: 36] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022] Open
Abstract
BACKGROUND Recent studies indicate that ambient temperature could be a risk factor for infectious diarrhea, but evidence for such a relation is limited in China. METHODS We investigated the short-term association between daily temperature and physician-diagnosed infectious diarrhea during 2008-2010 in Shanghai, China. We adopted a time-series approach to analyze the data and a quasi-Poisson regression model with a natural spline-smoothing function to adjust for long-term and seasonal trends, as well as other time-varying covariates. RESULTS There was a significant association between temperature and outpatient visits for diarrhea. A 1°C increase in the 6-day moving average of temperature was associated with a 2.68% (95% CI: 1.83%, 3.52%) increase in outpatient visits for diarrhea. We did not find a significant association between rainfall and infectious diarrhea. CONCLUSIONS High temperature might be a risk factor for infectious diarrhea in Shanghai. Public health programs should focus on preventing diarrhea related to high temperature among city residents.
Collapse
Affiliation(s)
- Xiaodan Zhou
- School of Public Health, Key Lab of Public Health Safety of the Ministry of Education, Fudan University
| | | | | | | | | | | |
Collapse
|
6
|
Paulke-Korinek M, Kollaritsch H, Aberle SW, Zwazl I, Schmidle-Loss B, Vécsei A, Kundi M. Sustained low hospitalization rates after four years of rotavirus mass vaccination in Austria. Vaccine 2013; 31:2686-91. [PMID: 23597718 DOI: 10.1016/j.vaccine.2013.04.001] [Citation(s) in RCA: 59] [Impact Index Per Article: 5.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/30/2013] [Revised: 03/15/2013] [Accepted: 04/02/2013] [Indexed: 11/27/2022]
Abstract
This hospital based surveillance study evaluates the effects of the rotavirus mass vaccination program, which was initiated in Austria in August 2007. Since then, incidence rates of rotavirus hospitalizations in children <15 years of age have decreased by 70% and 64% in 2010 and 2011 compared to the pre-vaccination era (2001-2005). Incidence rates were highest in children <90 days of age, highlighting the importance of the early start of active rotavirus immunization. In children between 2 and 3.5 years in 2011, who were in the second and third year after vaccination in the universal mass vaccination program, incidence rates remained low suggesting sustained protection after vaccination up to three years. In the years 2010 and 2011, field effectiveness of the vaccines was between 79% and 96%, depending on the assumptions made for children without information on vaccination history. From genotyping an increase of the prevalence of G2P[4] in children with breakthrough infection (disease despite vaccination) can be suspected. The rate of severe adverse events was 1.3-1.5 per 10(-5) administered doses of rotavirus vaccines and no death, intussusception or Kawasaki disease was reported in 2010 and 2011 following rotavirus vaccination.
Collapse
Affiliation(s)
- Maria Paulke-Korinek
- Institute of Specific Prophylaxis and Tropical Medicine, Medical University Vienna, Austria
| | | | | | | | | | | | | |
Collapse
|
7
|
Zlamy M, Kofler S, Orth D, Würzner R, Heinz-Erian P, Streng A, Prelog M. The impact of Rotavirus mass vaccination on hospitalization rates, nosocomial Rotavirus gastroenteritis and secondary blood stream infections. BMC Infect Dis 2013; 13:112. [PMID: 23452879 PMCID: PMC3599253 DOI: 10.1186/1471-2334-13-112] [Citation(s) in RCA: 51] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/05/2012] [Accepted: 02/27/2013] [Indexed: 11/12/2022] Open
Abstract
Background The aim of the study was to evaluate the effects of universal mass vaccination (UMV) against rotavirus (RV) on the hospitalization rates, nosocomial RV infections and RV-gastroenteritis (GE)-associated secondary blood stream infections (BSI). Methods The retrospective evaluation (2002–2009) by chart analysis included all clinically diagnosed and microbiologically confirmed RV-GE cases in a large tertiary care hospital in Austria. The pre-vaccination period (2002–2005) was compared with the recommended and early funded (2006–2007) and the funded (2008–2009) vaccination periods. Primary outcomes were RV-GE-associated hospitalizations, secondary outcomes nosocomial RV disease, secondary BSI and direct hospitalization costs for children and their accompanying persons. Results In 1,532 children with RV-GE, a significant reduction by 73.9% of hospitalized RV-GE cases per year could be observed between the pre-vaccination and the funded vaccination period, which was most pronounced in the age groups 0–11 months (by 87.8%), 6–10 years (by 84.2%) and 11–18 years (88.9%). In the funded vaccination period, a reduction by 71.9% of nosocomial RV-GE cases per year was found compared to the pre-vaccination period. Fatalities due to nosocomial RV-GE were only observed in the pre-vaccination period (3 cases). Direct costs of hospitalized, community-acquired RV-GE cases per year were reduced by 72.7% in the funded vaccination period. The reduction of direct costs for patients (by 86.9%) and accompanying persons (86.2%) was most pronounced in the age group 0–11 months. Conclusions UMV may have contributed to the significant decrease of RV-GE-associated hospitalizations, to a reduction in nosocomial RV infections and RV-associated morbidity due to secondary BSI and reduced direct hospitalization costs. The reduction in nosocomial cases is an important aspect considering severe disease courses in hospitalized patients with co-morbidities and death due to nosocomial RV-GE.
Collapse
Affiliation(s)
- Manuela Zlamy
- Department of Pediatrics, Pediatrics I, Innsbruck Medical University, Anichstr, 35, 6020, Innsbruck, Austria
| | | | | | | | | | | | | |
Collapse
|
8
|
Soltani M, Bouanene I, Trabelsi A, Harbi A, Hachicha M, Amri F, Boussnina S, Gueddiche MN, Sfar MT, Teleb N, Ben Ghorbel M, Ben Hamida E. [Epidemiology of rotavirus gastroenteritis among children under 5 years of age in Tunisia - results of sentinel hospital surveillance 2009 to 2011]. Rev Epidemiol Sante Publique 2012; 60:473-80. [PMID: 23141818 DOI: 10.1016/j.respe.2012.04.005] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/12/2011] [Revised: 03/02/2012] [Accepted: 04/05/2012] [Indexed: 11/25/2022] Open
Abstract
BACKGROUND Rotavirus is the major cause of severe acute gastroenteritis among young children. The objectives of this study were to assess the epidemiology, clinical and virological features of community-acquired rotavirus acute gastroenteritis, in children under 5 years of age, hospitalized in Tunisia. METHODS A multicenter prospective observational study was conducted from April 2009 to March 2011, in 11 sentinel pediatric departments. Clinical data and stool samples were collected for all children under 5 years, admitted for acute gastroenteritis. Rotavirus was detected by Elisa immunoassay test and genotyped for G and P by semi-nested multiplex RT-PCR. RESULT A total of 621 children were enrolled in this study. Rotavirus was detected in 30.3% of cases (95% CI [26.7-33.9]). The estimated incidence rate of rotavirus acute gastroenteritis was 11 cases/100,000 child-years (95% CI [9.43-12.57]). This infection affected predominantly children aged under 24 months, and occurred mainly in winter (55.3%). Vomiting, fever and dehydration were observed in 79.6%, 69.5% and 57% respectively. Genotype analysis identified four G types (G1, G2, G3 and G4) and 4 P types (P[4], P[6], P[8] and P[9]). The most common G/P combination was G3P[8] (24.4%), followed by G4P[8] (13.3%) and G1P[8] (6.5%). CONCLUSION These results highlight the frequency and potential severity of rotavirus acute gastroenteritis in pediatric hospital settings. The present study could provide a sufficient database to make a decision related to the introduction of rotavirus vaccine in Tunisian national immunization program.
Collapse
Affiliation(s)
- M Soltani
- Service de médecine préventive et d'épidémiologie, CHU Fattouma Bourguiba, 5000 Monastir, Tunisie.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
9
|
Paulke-Korinek M, Kundi M, Rendi-Wagner P, de Martin A, Eder G, Schmidle-Loss B, Vecsei A, Kollaritsch H. Herd immunity after two years of the universal mass vaccination program against rotavirus gastroenteritis in Austria. Vaccine 2011; 29:2791-6. [PMID: 21320539 DOI: 10.1016/j.vaccine.2011.01.104] [Citation(s) in RCA: 95] [Impact Index Per Article: 7.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/13/2010] [Revised: 01/12/2011] [Accepted: 01/30/2011] [Indexed: 11/27/2022]
|
10
|
Panatto D, Amicizia D, Giacchino R, Tacchella A, Natalizia AR, Melioli G, Bandettini R, Pietro P, Diana MC, Gasparini R. Burden of rotavirus infections in Liguria, northern Italy: hospitalisations and potential savings by vaccination. Eur J Clin Microbiol Infect Dis 2011; 30:957-64. [DOI: 10.1007/s10096-011-1180-7] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/09/2010] [Accepted: 01/14/2011] [Indexed: 11/28/2022]
|
11
|
Abstract
BACKGROUND rotavirus (RV) infection is the leading cause of acute gastroenteritis in young children worldwide. In 2006, 2 live-attenuated RV-vaccines became available for use in infants ≤ 6 months of age. In Germany, a statutory notification system for RV infection has been in place since 2001 to monitor RV epidemiology. Our objective was to assess RV disease burden in German children <5 years of age. METHODS Detailed descriptive analysis of national RV surveillance data in children <5 years of age collected in Germany between January 2001 and December 2008. RESULTS between 2001 and 2008, 72% of all notified RV patients were children <5 years of age. The highest annual incidence (approximately, 200/10,000) was in children <2 years of age. In the <5 years age-group, approximately 50% of reported patients were hospitalized and of those, 9% acquired the infection nosocomially. Since 2004, a total of 8 children <5 years of age were reported as RV-associated deaths, and case fatality due to RV infection was <0.01/10,000. CONCLUSIONS the high incidence of RV infection and RV-associated hospitalization in children <5 years of age results in a high disease burden. Routine childhood RV vaccination would be a measure to reduce the burden in this age-group. However, cost-effectiveness analyses specific to the German setting should be considered in the decision-making process. An RV-surveillance system is in place in Germany that could potentially monitor the effect of an RV-vaccination program once implemented.
Collapse
|
12
|
Universal mass vaccination against rotavirus gastroenteritis: impact on hospitalization rates in austrian children. Pediatr Infect Dis J 2010; 29:319-23. [PMID: 19935446 DOI: 10.1097/inf.0b013e3181c18434] [Citation(s) in RCA: 89] [Impact Index Per Article: 6.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
Abstract
BACKGROUND Since July 2007, rotavirus vaccinations have been subsidized in Austria for all children from the seventh week up to the sixth month of life. Vaccination coverage over the whole period was 72% with an increase to 87% in 2008. METHODS In a sentinel network including 11 pediatric hospital wards in Austria, data of children up to 15 years of age and hospitalized due to rotavirus gastroenteritis between January 2001 and December 2008 have been collected. RESULTS The hospitalization rates of children up to 12 months of age with rotavirus gastroenteritis were 2066 x 10(-5) between 2001 and 2006 and decreased to 631 x 10(-5) in 2008. For children between 12 and 24 months of age the hospitalization rate decreased from 1822 x 10(-5) (2001-2006) to 1456 x 10(-5) in 2008. In children aged 2 to less than 5 years, incidence rates were 436 x10(-5) (2001-2006) and 461 x 10(-5) in 2008. In older children, the hospitalization rates remained unchanged. In the target population for the RV-vaccine, a decrease of hospitalization rates due to rotavirus gastroenteritis of 74% was observed compared to the era before the introduction of the vaccine. The field effectiveness of the vaccine was estimated between 61% and 98%, depending on assumptions about the vaccination status. CONCLUSIONS Within 18 months, the universal mass vaccination program against rotavirus led to a substantial decrease in the hospitalization rates of the target cohort of the immunization program in Austria.
Collapse
|
13
|
Lacroix L, Galetto-Lacour A, Altwegg M, Egli K, Schmidt M, Gervaix A. Disease burden of rotavirus gastroenteritis in children up to 5 years of age in two Swiss cantons: paediatrician- and hospital-based surveillance. Eur J Pediatr 2010; 169:319-25. [PMID: 19649782 DOI: 10.1007/s00431-009-1032-y] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/17/2009] [Accepted: 07/08/2009] [Indexed: 10/20/2022]
Abstract
Rotavirus gastroenteritis (RV GE) is a leading cause of diarrhoea in young children. The purpose of this epidemiological surveillance was to measure the disease burden of RV GE among children <5 years of age in two regions of Switzerland, Geneva and Lucerne. One hospital and four paediatricians participated per region. The surveillance lasted from December 2006 to June 2007. The population denominator for calculation of the RV GE incidence rate was the average of the overall study population <5 years of age under surveillance during the surveillance period. At the study sites, 513 children with GE were presented. Stool sample was collected and examined in 341 cases, of which 130 were RV positive (38.1%). Informed consent to participate in the study was obtained for 113 RV positive subjects. The overall RV GE incidence rate was 0.97% in Lucerne [lower incidence interval (LCI), 0.71%; upper incidence interval (UCI), 1.2%] compared with 0.65 and in Geneva (LCI, 0.50%; UCI, 0.81%). Disease severity assessments using the Vescari score showed that the RV GE episodes were more severe in Lucerne than in Geneva (14.05 +/- 3.05 vs 12.85 +/- 2.87), which was confirmed by a higher hospitalisation rate in Lucerne at the study visit (82.9% vs 23.6%). More children had fever in Geneva than in Lucerne (42.9% vs 26.8%), and more children were hospitalised during the follow-up period in Geneva than in Lucerne (14.5% vs 2.5%). Genotyping of RV positive stool samples revealed that both G1 and P8 were the most prevalent types in both regions. There was a statistically significant difference in the distribution frequency of G1 between the two regions (p = 0.039). Assessment of health economic data confirmed the economic burden of RV GE episodes. In conclusion, RV GE episodes are a health burden as well as an economic burden also for the children in a developed country such as Switzerland.
Collapse
Affiliation(s)
- Laurence Lacroix
- Child and Adolescent Department, University Hospital of Geneva, 6 rue Willy-Donzé, 1211 Geneva, Switzerland
| | | | | | | | | | | |
Collapse
|
14
|
Matthijnssens J, Bilcke J, Ciarlet M, Martella V, Bányai K, Rahman M, Zeller M, Beutels P, Van Damme P, Van Ranst M. Rotavirus disease and vaccination: impact on genotype diversity. Future Microbiol 2010; 4:1303-16. [PMID: 19995190 DOI: 10.2217/fmb.09.96] [Citation(s) in RCA: 257] [Impact Index Per Article: 18.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/15/2023] Open
Abstract
Temporal and spatial fluctuations in the genotype distribution of human rotaviruses are continuously observed in surveillance studies. New genotypes, such as G9 and G12, have emerged and spread worldwide in a very short time span. In addition, reassortment events have the potential to contribute substantially to genetic diversity among human and animal rotaviruses. With the recent introduction of the two rotavirus vaccines, RotaTeq and Rotarix, in many countries, it appears that the total number of hospitalizations due to rotavirus infections is being reduced, at least in developed countries that implemented a universal immunization program. However, continued surveillance is warranted, especially regarding the long-term effects of the vaccines. No data analyses are available to clarify whether rotavirus vaccine introduction would allow other rotavirus P and G genotypes, which are not covered by the current vaccines, to emerge into the human population and fill the apparent gap. This kind of data analysis is essential, but its interpretation is hampered by natural and cyclical genotype fluctuations.
Collapse
Affiliation(s)
- Jelle Matthijnssens
- Laboratory of Clinical and Epidemiological Virology, Department of Microbiology & Immunology, Rega Institute for Medical Research, University of Leuven, Leuven, Belgium.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
15
|
Fournel I, Soulias M, Bour JB, Gouyon JB, Huet F, Aho LS. [Evolution of the number of rotavirus and respiratory syncytial virus infections in children hospitalised in a French university hospital between 1998 and 2005]. ACTA ACUST UNITED AC 2008; 58:406-14. [PMID: 19081201 DOI: 10.1016/j.patbio.2008.10.003] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/24/2008] [Accepted: 10/17/2008] [Indexed: 10/21/2022]
Abstract
AIM Respiratory syncytial virus (RSV) and Rotavirus infections represent up to 30% of cross infections in pediatric units. As they are a major public health problem, we studied their evolution and distribution at the Dijon University Hospital. POPULATION AND METHODS This exhaustive retrospective study included children under 15 with a new Rotavirus or RSV infection who were hospitalised at the Dijon University Hospital between 1998 and 2005. The general trend was determined by using moving averages, and the Spearman correlation coefficient r(s) was calculated. RESULTS From 1998 to 2005, 1886 new RSV (n=981) or Rotavirus (n=905) infections were identified in hospitalised children. The number of the infections decreased significantly, both for RSV (r(s)=-0.71 ; p<0.0001) and for Rotavirus (r(s)=-0.77 ; p<0.0001). Almost half of Rotavirus infections were nosocomial (46.3%) vs 5.3% of RSV infections, p<0.0001. There was no significant difference in the proportion of RSV nosocomial infections between the epidemic and non-epidemic period (4.9% of nosocomial infections vs 7.1% respectively, p=0.25). Rotavirus nosocomial infections were less frequent in epidemic period (41.6%) than in non-epidemic period (54.6%); p=0.0002. CONCLUSION RSV and Rotavirus infections significantly decreased between 1998 and 2005. Proportion of RSV or Rotavirus infections didn't increase in epidemic period, which could be explained both by an increased attention from healthcare professionals and by the effectiveness of hygiene measures taken.
Collapse
Affiliation(s)
- I Fournel
- Service d'hygiène et d'épidémiologie hospitalière, pôle des pathologies lourdes et des vigilances, CHU de Dijon, 1, boulevard Jeanne-d'Arc, 21079 Dijon cedex, France.
| | | | | | | | | | | |
Collapse
|
16
|
Wiedermann U, Kollaritsch H. Vaccines against traveler's diarrhoea and rotavirus disease - a review. Wien Klin Wochenschr 2007; 118:2-8. [PMID: 17131234 DOI: 10.1007/s00508-006-0671-5] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
Abstract
Diarrheal diseases constitute one of the most important health problems worldwide, preferentially in developing countries with a morbidity of estimated 5 billion and a mortality of 5 million cases per year. Children less than 5 years are particularly in danger with respect to the incidence and severity of the gastrointestinal symptoms. Travelers to developing countries are also at risk to develop diarrheal disorders; around 30-50% of them acquire so called "travelers's diarrhea" caused by bacteria, viruses or protozoa. It has been estimated that approximately 30-70% of diarrhea are due to bacteria, of which the most frequently detected enteric pathogens are non-invasive, enterotoxigenic Escherichia coli (ETEC). Their exotoxins, the heat stabile (ST) and the heat labile (LT) toxins are in large part responsible for the pathogenicity of the bacteria. About 20% of cases of traveler's diarrhea are caused by LT producing ETEC. This heat labile toxin exhibits a 80% sequence homology with cholera toxin. The presently available vaccine against cholera (Dukoral) contains inactivated Vibrio cholerae bacteria and the recombinant non-toxic B subunit of cholera toxin. Consequently, this vaccine displays also some efficacy against traveler's diarrhoea with up to 25% of travelers being protected against this disease. Rotaviruses are the leading recognized cause of diarrhoea-related illness and deaths among infants worldwide in developing and industrialized countries. Based on the high incidence of this disease two oral vaccines have been developed and will be available in Europe in 2006. Due to the impact of rotavirus diseases also in Austria vaccination against this disease has been already suggested in the Austrian vaccination schedules for infants from 6-24 weeks of age. One of the two vaccines, Rotarix, is an attenuated monovalent vaccine with a broad cross-reactivity against the most frequent serotypes. The second one, RotaTeq, is a pentavalent attenuated vaccine containing 5 human-bovine reassortants. Both vaccines display 85-98% efficacy against severe rotavirus disease and an excellent tolerability with no difference in side reactions to the placebo controls, particularly with respect to intussusceptions. With respect to increasing travel habits with infants and small children, particularly when visiting friends and relatives, vaccination against rotavirus infections will also be important in international travel.
Collapse
Affiliation(s)
- Ursula Wiedermann
- Department of Specific Prophylaxis and Tropical Medicine, Center for Physiology and Pathophysiology, Medical University of Vienna, Vienna, Austria.
| | | |
Collapse
|
17
|
Kollaritsch H, Wiedermann U. [Examples for vaccines against diarrheal diseases--rotavirus and traveller's diarrhea]. Wien Med Wochenschr 2007; 157:102-6. [PMID: 17427005 DOI: 10.1007/s10354-007-0390-1] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/29/2006] [Accepted: 12/28/2006] [Indexed: 10/23/2022]
Abstract
Diarrheal diseases constitute one of the most important health problems worldwide. Children less than 5 years, living in developing countries, are particularly in danger with respect to the incidence and severity of the gastrointestinal disorders. Travelers to developing countries are also at risk to develop diarrheal disorders; around 30-50% of them acquire so called "travelers's diarrhea" caused by bacteria, viruses or protozoa. It has been estimated that approximately 30-70% of diarrhea are due to bacteria, of which the most frequently detected enteric pathogens are non-invasive, enterotoxigenic Escherichia coli (ETEC). Their exotoxins, the heat stabile (ST) and the heat labile (LT) toxins are in large part responsible for the pathogenicity of the bacteria. About 20% of cases of traveler's diarrhea are caused by LT producing ETEC. This heat labile toxin exhibits a 80% sequence homology with cholera toxin. The presently available vaccine against cholera (Dukoral) contains inactivated Vibrio cholerae bacteria and the recombinant non-toxic B subunit of cholera toxin. Consequently, this vaccine displays also some efficacy against traveler's diarrhoea with up to 25 % of travelers being protected against this disease. Rotaviruses are the leading recognized cause of diarrhoea-related illness and deaths among infants worldwide in developing and industrialized countries. Based on the high incidence of this disease two oral vaccines have been developed and are available in Europe in 2007. Due to the impact of rotavirus diseases also in Austria vaccination against this disease has been already suggested in the Austrian vaccination schedules for infants from 6-24 weeks of age. One of the two vaccines, Rotarix, is an attenuated monovalent vaccine with a broad cross-reactivity against the most frequent serotypes. The second one, RotaTeq, is a pentavalent attenuated vaccine containing 5 human-bovine reassortants. Both vaccines display 85-98% efficacy against severe rotavirus disease and an excellent tolerability with no difference in side reactions to the placebo controls, particularly with respect to intussusceptions.
Collapse
Affiliation(s)
- Herwig Kollaritsch
- Institut für Spezifische Prophylaxe und Tropenmedizin, Zentrum für Physiologie und Pathophysiologie, Medizinische Universität Wien, Kinderspitalgasse 15, Vienna, Austria.
| | | |
Collapse
|
18
|
Höhl R. Impfplan 2007 – Details zur Rotavirusimpfung. Wien Med Wochenschr 2007; 157:133-5. [PMID: 17427011 DOI: 10.1007/s10354-007-0401-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|